Value-based pricing concepts laid out

Journal of American Medical Association
May 2, 2018

The term “value-based pricing” has been adopted by pharmaceutical companies, payers and policy makers to refer to a range of payment models that break with convention. However, their potential for aligning a drug’s price with its value varies substantially. In a JAMA Viewpoint, DPL’s Anna Kaltenboeck and Dr. Peter Bach offer a taxonomy of the features that make a payment model truly value-based.